Biogen MA Inc. v. EMD Serono, Inc.

 
DOCKET NO.
OP. BELOW
SUBJECT
Patent

Question(s) Presented

“Whether courts may disregard the express claim term ‘recombinant’ so as to render a method-of-treatment patent anticipated—and thus invalid—in light of prior-art treatments that used the naturally occurring human protein, where it is undisputed that the recombinant protein was not used in the prior art?”

Posts About this Case

Date
Proceedings and Orders
June 8, 2021
Motion to extend the time to file a response is granted and the time is extended to and including July 19, 2021.
August 4, 2021
DISTRIBUTED for Conference of 9/27/2021.
October 4, 2021
Petition DENIED.